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 Lyme disease is the fastest growing vector-borne disease in the 
United States, according to the Infectious Disease Society of 
America (IDSA).  The guidelines for diagnosis provided by the 
IDSA include evidence of erythema migrans rash with validation of 
a positive two-tier serology testing.  With no established treatment 
standards, decreased sensitivity of testing and inconsistency of 
observing the rash, practitioners following the guidelines may delay 
treatment of antibiotics. This delay could cause progression of 
severity of symptoms.  
 The purpose of this study is to compare implementation and 
duration time of antibiotics and establish the treatment protocol for  
best clinical outcomes for Lyme disease.  Diagnosis will be based on 
practitioner’s clinical judgment with or without positive serology 
testing and erythema rash. Review of literature will define late, 
chronic and recurrent Lyme disease, describe recurrent treatment of 
Lyme disease, compare and contrast present protocols with different 
duration and types of antibiotics, and examine markers and  
subjective reports as evidence of improvement. Guidelines and 
recommendations will be provided from Lyme disease experts.    
 Significant results found that early implemented, shorter 
duration antibiotic use provided the greatest clinical improvement 
long term.  
• In patients with clinical symptoms of Lyme disease, is early 
intervention (within 4-6 weeks of clinical diagnosis) of 
antibiotics more beneficial in reduction of subjective 
symptoms than treatment implemented after 6 weeks? 
• In patients with clinical symptoms of Lyme disease, would 
shorter duration antibiotics (14 days) be more beneficial than 
longer duration (28 days) in reduction of subjective symptom? 
   
Appropriate treatment protocols for Lyme disease have not been 
established for best clinical outcomes.  Comparisons have been 
made of immediate, short duration antibiotic use versus delayed, 
longer duration use. Concern arises regarding long term 
antibiotic use and antibiotic resistance so evidence is needed to 
validate appropriate treatment choices.  
• Practitioners need to be educated in proper diagnosis and    
treatment of Lyme disease by pattern recognition instead of   
unreliable serology tests and presence of rash. This will provide 
flexibility in the care and prompt treatment of the Lyme patient. 
• Early detection of Lyme disease could allow for  prompt 
antibiotic treatment of shorter duration allowing for better use of 
medical resources.  The patient would benefit from less antibiotic 
use with improved symptoms, without the fear of antibiotic 
resistance or other side effects.   
• Conclusions gathered from studies analyzed are to educate 
communities to recognize the signs and symptoms of Lyme 
disease in order to be advocates in prompt, shorter duration 
treatment for best clinical outcomes.    
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• According to the Centers of Disease Control and Prevention         
(CDC, 2008) 40,792 Lyme disease cases were reported in the US in 
2001-2002, a 40% increase from the previous year. Individual 
Lyme clinics indicate that the number of Lyme disease cases may 
be ten times higher.  
• The guidelines for diagnosis provided by  IDSA contribute to       
misdiagnosis as erythema migrans rash is not observed  in up to    
60% of cases with sensitivity of  two-tier serology testing (ELISA 
and Western Blot) being 50%.  
• Delay in treatment could cause progression to chronic Lyme 
disease which is more resistant to treatment with more severe 
symptoms. 
• Debate continues about appropriate use of antibiotics, including 
type, implementation time and duration in order to reach maximal 
benefit of symptom relief.    
• Appropriate protocols for use of antibiotics are necessary for 
improved treatment of Lyme disease.  
• Early implemented (two to six weeks after tick bite), shorter duration 
    antibiotics (14 days)  provided the greatest clinical improvement, long    
term for Lyme disease.  
•   Resolution of erythema migrans rash and systemic symptoms could be 
achieved with 10 days dosage as readily as 20 days so minimal 
antibiotics are as effective as longer term use. 
•   Longer term use of antibiotics (greater than four weeks) may be useful 
and justified in people with persistent symptoms and co-infection of 
the tick. 
•  Time of implementation of the antibiotic is a component of successful 
treatment, emphasis on prompt treatment (no later than 6 weeks). 
•  Tetracycline, doxycycline, or amoxicillin antibiotics should be used in 
the acute phases.  Ceftriaxone (especially for neurological symptoms) 
and intravenous penicillin have been shown to be beneficial for later 
stages and more advanced symptoms. 
•   Due to lack of  exact consistent presentation of symptoms; clinical 
data, history, and physical exam become especially important. 
•   Clusters of symptoms (pattern recognition) all in the same time frame 
is more indicative of Lyme disease versus one symptom. 
•   Using patient’s symptom report to monitor success of the treatment 
could make decision making easier for the practitioner and help with 
individualized care. 
•   No test for a cure so knowing when to discontinue antibiotics is 
difficult.   
•   Unknown if chronic Lyme disease is an active persistent infection or 
the result of the acute Lyme process. Treatment protocol would differ 
and could include combination of antibiotics for persistent strains. 
•   Possible future diagnostic tool using the C6 antibody marker. 
 
 
• Borrelia burgdorferi, the Lyme spirochete, is transmitted to humans by 
the bite of an infected Ixodes scapularis tick, which travels on white 
mice and deer.  
• The common symptoms after a tick bite include an erythema migran or 
bull’s eye rash and joint swelling, typical of arthritis.   
• Four to six weeks after the bite, the flu like systemic  infection begins.     
• Symptoms may progress to include paresthesia and other neurologic 
symptoms.  
• Classifications of Lyme disease: early stage, occurring days or weeks 
after initial infection, is a localized, single erythema with no other 
symptoms.   Early disseminated stage includes multiple rash lesions, 
and other symptoms involving joints, muscles, hearing or nerves; and 
lymphadenopathy; occurring weeks to months after infection.  The late 
or chronic disseminated stage Lyme disease presents months to years 
after infection.   
• The ELISA is the first screening test and if negative, practitioners are 
advised to not proceed to the Western Blot even though this test is 
highly specific to antibodies for Lyme disease. 
• Delayed treatment is strongly associated with treatment failure (up to 
58%) and a major risk factor for developing chronic Lyme disease.   
• Length of treatment is practitioner specific, associated with 
classification of Lyme disease. 
• The defense of the effectiveness of a short course of antibiotics was 
validated in various studies. 
 
